23.07.2015 • News

Emerald Kalama to Expand Benzoic Acid

Emerald Kalama Chemical, a part of Emerald Performance Materials, will add a second 100,000 t/y train for its high purity benzoic acid sold under the Purox B trademark and at the same time increase production capability for benzaldehyde at its facility in Rotterdam, the Netherlands up to late 2016.

The expanded production is designed to support growing demand for the company’s benzoic acid flakes, sodium benzoate granules and liquid benzoic acid, used in food and beverage, personal care, pharmaceutical and a variety of industrial applications.

Benzoic acid and benzaldehyde from the company’s reactor train are key intermediates used for to make products such as plasticizers and aroma chemicals.

“Reassessing our long-term strategic plan for our key intermediates, our expectations for benzoic acid continue to show strong growth and track according to plan,” said Hubert Degens, vice president of the Emerald Kalama Chemical Benzoates and Intermediates business.

“In addition,” Degens said, “our recent acquisition of Innospec Widnes’s aroma chemical business and growth plans for that platform are in line with our increased production capacity for benzaldehyde.”

The company has been producing benzoic acid at its Rotterdam and US operations for more than 50 years. Emerald Kalama Chemical’s portfolio of benzoic acid products is FDA-approved and GRAS-classified. The Rotterdam operation is also certified to meet or exceed a number of important quality standards.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read